Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript November 5, 2024Apellis Pharmaceuticals, Inc. misses on earnings expectations.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 11,890,843 | $342,931,912 | +3% | 11.73% |
| 2. | VenBio Select Advisor Kurt Von Emster | 11,111,111 | $320,444,441 | 4.67% | |
| 3. | Deep Track Capital David Kroin | 4,400,654 | $126,914,861 | +77% | 4.02% |
| 4. | Braidwell LP Alex Karnal | 3,125,183 | $90,130,278 | +411% | 2.55% |
| 5. | Octagon Capital Advisors Ting Jia | 3,006,980 | $86,721,303 | +5% | 13.48% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.79 | 7,524 | 100,000 | 2024-09-16 | Filing | ||
| $36.09 | 29,476 | 107,524 | 2024-09-16 | Filing | ||
| $36.21 | 192 | Officer | 38,141 | 2024-09-16 | Filing | |
| $39.49 | 550 | Officer | 38,333 | 2024-09-03 | Filing | |
| $39.63 | 1,695 | 136,998 | 2024-06-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,445,290 | $984,415,060 | 0.18% | |
| 2. | 9,555,678 | $572,002,885 | 0.01% | |
| 3. | 5,381,253 | $322,121,807 | 0% | |
| 4. | 3,275,922 | $196,096,693 | 0.14% | |
| 5. | 3,097,141 | $185,394,859 | 0.01% |
News See All
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Below we present the list of 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.